{"title":"Abiraterone醋酸。","authors":"","doi":"10.2165/11587960-000000000-00000","DOIUrl":null,"url":null,"abstract":"<p><p>Abiraterone acetate (CB 7630; CB7630; JNJ-212082), the 3β-acetate prodrug of abiraterone, is structurally related to ketoconazole and is being developed by Cougar Biotechnology as a hormonal therapy for advanced prostate and breast cancers. As a selective inhibitor of adrenal androgens, it is thought to be a safer product than existing second-line hormonal therapies. This review discusses the key development milestones and therapeutic trials of this drug.</p>","PeriodicalId":11373,"journal":{"name":"Drugs in R & D","volume":" ","pages":"261-9"},"PeriodicalIF":0.0000,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2165/11587960-000000000-00000","citationCount":"0","resultStr":"{\"title\":\"Abiraterone acetate.\",\"authors\":\"\",\"doi\":\"10.2165/11587960-000000000-00000\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Abiraterone acetate (CB 7630; CB7630; JNJ-212082), the 3β-acetate prodrug of abiraterone, is structurally related to ketoconazole and is being developed by Cougar Biotechnology as a hormonal therapy for advanced prostate and breast cancers. As a selective inhibitor of adrenal androgens, it is thought to be a safer product than existing second-line hormonal therapies. This review discusses the key development milestones and therapeutic trials of this drug.</p>\",\"PeriodicalId\":11373,\"journal\":{\"name\":\"Drugs in R & D\",\"volume\":\" \",\"pages\":\"261-9\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2165/11587960-000000000-00000\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drugs in R & D\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2165/11587960-000000000-00000\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs in R & D","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2165/11587960-000000000-00000","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abiraterone acetate (CB 7630; CB7630; JNJ-212082), the 3β-acetate prodrug of abiraterone, is structurally related to ketoconazole and is being developed by Cougar Biotechnology as a hormonal therapy for advanced prostate and breast cancers. As a selective inhibitor of adrenal androgens, it is thought to be a safer product than existing second-line hormonal therapies. This review discusses the key development milestones and therapeutic trials of this drug.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
